Neovacs S.A Verschuldung / Eigenkapital
Was ist das Verschuldung / Eigenkapital von Neovacs S.A?
Verschuldung / Eigenkapital von Neovacs S.A. ist 0.08
Was ist die Definition von Verschuldung / Eigenkapital?
Die Verschuldung zu Eigenkapital ist ein Finanzverhältnis, das den relativen Anteil des Eigenkapitals und der Verschuldung angibt, die zur Finanzierung der Vermögenswerte eines Unternehmens verwendet werden.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Verschuldung / Eigenkapital von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Neovacs S.A
Was macht Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Unternehmen mit verschuldung / eigenkapital ähnlich Neovacs S.A
- Invex Therapeutics Ltd hat Verschuldung / Eigenkapital von 0.08
- Engineer Gold Mines hat Verschuldung / Eigenkapital von 0.08
- Bajaj & Investment hat Verschuldung / Eigenkapital von 0.08
- Little Fish Acquisition I hat Verschuldung / Eigenkapital von 0.08
- Yatra Capital hat Verschuldung / Eigenkapital von 0.08
- AIA Engineering hat Verschuldung / Eigenkapital von 0.08
- Neovacs S.A hat Verschuldung / Eigenkapital von 0.08
- Kestrel Gold hat Verschuldung / Eigenkapital von 0.08
- Sherpa II hat Verschuldung / Eigenkapital von 0.08
- Appulse hat Verschuldung / Eigenkapital von 0.08
- Alphawave IP plc hat Verschuldung / Eigenkapital von 0.08
- Jessy Ventures hat Verschuldung / Eigenkapital von 0.08
- OD6 Metals hat Verschuldung / Eigenkapital von 0.08